PDF(Pubmed)
Abstract：
UNASSIGNED: Diabetes is a public health problem that requires strategies to impact glycemic control and reduce the risk of long-term medical complications. Pharmacological management is a necessary treatment for this disease. Therefore, semaglutide is an essential tool to achieve the treatment targets. The present study aimed to evaluate the semaglutide effects on a cohort with type 2 diabetes mellitus (T2DM) in Colombia.
UNASSIGNED: The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6- and 12-month follow-up.
UNASSIGNED: Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD -2.74 CI -1.95 to -3.52 in 6 months), fasting plasma glucose levels, body weight (MD -7.11 CI -5.97 to -8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events.
UNASSIGNED: This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.
UNASSIGNED: The cohort included 49 patients with T2DM that have been treated in a specialized care center. Their glycemic outcomes, weight, renal function, and adverse events were evaluated through a 3-, 6- and 12-month follow-up.
UNASSIGNED: Significant differences were observed in the outcome evaluation: reduction of glycated hemoglobin levels (MD -2.74 CI -1.95 to -3.52 in 6 months), fasting plasma glucose levels, body weight (MD -7.11 CI -5.97 to -8.24), and the albumin-to-creatinine ratio. The results were maintained throughout the treatment period. The adverse event rate was 16.3%, predominating gastrointestinal events.
UNASSIGNED: This real-world evidence shows the efficacy of semaglutide in achieving treatment goals in patients with T2DM.
摘要：
■糖尿病是一个公共卫生问题，需要采取策略来影响血糖控制并降低长期医疗并发症的风险。药物管理是这种疾病的必要治疗方法。因此,司马鲁肽是实现治疗目标的重要工具。本研究旨在评估semaglutide对哥伦比亚2型糖尿病（T2DM）队列的影响。
■该队列包括49名在专业护理中心接受治疗的T2DM患者。他们的血糖结果，体重,肾功能,和不良事件通过3-，6个月和12个月的随访。
■在结果评估中观察到显着差异：糖化血红蛋白水平降低（6个月内MD-2.74CI-1.95至-3.52），空腹血糖水平，体重（MD-7.11CI-5.97至-8.24），以及白蛋白与肌酐的比值.在整个治疗期间保持该结果。不良事件发生率为16.3%,以胃肠道事件为主。
■这个真实世界的证据显示了司马鲁肽在T2DM患者中实现治疗目标的功效。
■该队列包括49名在专业护理中心接受治疗的T2DM患者。他们的血糖结果，体重,肾功能,和不良事件通过3-，6个月和12个月的随访。
■在结果评估中观察到显着差异：糖化血红蛋白水平降低（6个月内MD-2.74CI-1.95至-3.52），空腹血糖水平，体重（MD-7.11CI-5.97至-8.24），以及白蛋白与肌酐的比值.在整个治疗期间保持该结果。不良事件发生率为16.3%,以胃肠道事件为主。
■这个真实世界的证据显示了司马鲁肽在T2DM患者中实现治疗目标的功效。
